Video

Don't Write Off Immunotherapy in Brain Cancer Just Yet

Author(s):

David Reardon, M.D.

Researchers should not give up hope in using immunotherapy to treat brain cancers.

Although negative results from trials evaluating immunotherapy and brain cancer were presented at the 2018 American Society of Clinical Oncology (ASCO) annual meeting, David Reardon, M.D., clinical director for the Center for Neuro-Oncology, Medical Oncology at the Dana-Farber Cancer Institute and associate professor of Medicine at Harvard Medical School, says that we shouldn’t write off the possibility of this treatment regimen just yet.

Brain cancers like glioblastoma (GBM) are notoriously difficult to treat, so it is going to take more research and hard work to determine how these agents can fit into the arsenal for treating GBM, he added.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Melanoma is a key cancer type for developing and testing immunotherapies prior to broader clinical application across other malignancies.
Image of Dr. Kumar.
Photo of a woman with shoulder-length black hair wearing a blazer
Image of a woman wearing a headband and glasses
Image of man.
Image of doctor.
CURE spoke with Andy Guinigundo to discuss the role that biomarkers play for patients with breast cancer.
Colorectal cancer is on the rise among younger adults, although potential explanations for the cause of this trend are likely years away.
Related Content
Illustration of brain.
April 15th 2025

Clinical Trial of NEO100 Recruiting Patients With Malignant Gliomas

Alex Biese
A phase 2a clinical trial of NEO100-01 is continuing to recruit patients with malignant gliomas, with full enrollment expected in September.
Site Logo
August 29th 2019

Earning Your Legacy: Cancer Has Nothing To Do With It

Kristie L. Kahl
In this episode of the “CURE Talks Cancer” podcast, we spoke with Matt Newman, who was diagnosed with brain cancer at 39, but refuses to let cancer define the legacy he has made.
The Food and Drug Administration has approved Avastin biosimilar Jobevne.
April 10th 2025

FDA Approves Avastin Biosimilar Jobevne Across Several Cancer Types

Alex Biese
The FDA has approved Jobevne, a biosimilar to Avastin, for IV use in a number of cancer types.
Site Logo
April 11th 2019

Addressing Nutritional Needs in Cancer

Kristie L. Kahl
In this week’s episode, we spoke with the founder and CEO of Savor Health on the importance of nutrition for patients and caregivers before, during and after cancer treatment.
image of dr. Lillian Siu.
April 3rd 2025

Breaking Down Early Signs and Symptoms of Head and Neck Cancer

Dr Lillian Siu
April is Head and Neck Cancer Awareness Month, and it is important to be aware of early signs and symptoms of the disease, as well as when to seek care.
The FDA has approved an application to initiate a pilot study with Alpha DaRT for patients with recurrent glioblastoma, a form of brain cancer.
April 2nd 2025

FDA Approves Initiation of a New Trial in Recurrent Glioblastoma

Ryan Scott
The FDA has approved an application to initiate a pilot study with Alpha DaRT for patients with recurrent glioblastoma, a form of brain cancer.